查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604727

异位性皮肤炎治疗市场：按药物类别、给药途径划分 - 2025-2030 年全球预测

Atopic Dermatitis Drugs Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable ROA, Oral ROA, Tropical ROA) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年异位性皮肤炎治疗市值为80.2亿美元，预计到2024年将达到85.6亿美元，复合年增长率为6.84%，到2030年将达到127.6亿美元，预计将达到1000万美元。

异位性皮肤炎 (AD) 药物包括控制和治疗异位性皮肤炎症状的药物。异位性皮肤炎是一种慢性发炎皮肤病，其特征是皮肤发痒和发炎。这些药物的需求源于异位性皮肤炎的全球流行，该疾病影响儿童和成人，并且需要有效的治疗方法。应用范围主要是局部、全身用药和生物製药，最终用户包括医院、药房、线上零售商和皮肤科诊所。关键的成长要素包括皮肤健康意识的提高、医疗保健支出的增加、生物技术的进步以及单株抗体和 JAK 抑制剂等创新药物产品线的不断扩大。最近的机会包括扩大使用针对高度特异性发炎途径的生物製药，以及个人化医疗根据基因谱量身订做治疗的潜力。然而，市场开拓面临着高昂的药物开发成本、监管障碍、大规模临床试验的需要、竞争激烈的市场动态以及与某些治疗相关的潜在副作用等挑战。为了抓住新的机会，相关人员正在推动研究和开发，以开发更有效、更安全的生技药品，探索自然疗法和替代疗法，并利用数位疗法来监测和管理 AD 症状。积极参与合作研究和伙伴关係可以促进知识转移和创新突破。此外，技术创新的目标是生产更具成本效益的配方并使其更容易获得。该市场竞争激烈、研究密集型，并且由于科学进步和以患者为中心的需求而不断发展，需要灵活的策略才能保持市场领先地位。

主要市场统计
基准年[2023] 80.2亿美元
预测年份 [2024] 85.6亿美元
预测年份 [2030] 127.6亿美元
复合年增长率（%） 6.84%

市场动态：快速发展的异位性皮肤炎治疗市场的关键市场洞察

供需的动态交互作用正在改变异位性皮肤炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 异位性皮肤炎盛行率增加
    • 食物过敏盛行率增加，导致异位性皮肤炎恶化
    • 开发保护皮肤屏障的新型保湿剂、生技药品及局部补脂药物
  • 市场限制因素
    • 治疗药物高成本
  • 市场机会
    • 治疗方法意识不断增强
    • 增加各个开发中国家获得治疗的机会
  • 市场挑战
    • 与药物相关的副作用

波特五力：驾驭异位性皮肤炎药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解异位性皮肤炎治疗药物市场的外部影响

外部宏观环境因素在塑造异位性皮肤炎治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解异位性皮肤炎治疗药物市场的竞争状况

对异位性皮肤炎治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵异位性皮肤炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估异位性皮肤炎治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘异位性皮肤炎治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对异位性皮肤炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 异位性皮肤炎的发生率增加
      • 食物过敏的增加正在加剧异位性皮肤炎
      • 保护皮肤屏障的新型保湿剂、生技药品、外用补脂药物的开发
    • 抑制因素
      • 治疗费用上涨
    • 机会
      • 提高对该疾病治疗方法可用性的认识
      • 扩大各个新兴国家获得治疗的机会
    • 任务
      • 与药物使用相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 异位性皮肤炎治疗药物市场（依药物类别）

  • 生物製药
  • Calcineurin抑制剂
  • 皮质类固醇
  • 磷酸二酯酶4抑制剂

第七章 异位性皮肤炎治疗药物市场：依给药途径

  • 可注射的ROA
  • 口服ROA
  • 热带ROA

第八章 北美和南美异位性皮肤炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太特应性皮肤炎治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲异位性皮肤炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma SA
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
  • Meda AB
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436901065D12

The Atopic Dermatitis Drugs Market was valued at USD 8.02 billion in 2023, expected to reach USD 8.56 billion in 2024, and is projected to grow at a CAGR of 6.84%, to USD 12.76 billion by 2030.

Atopic dermatitis (AD) drugs encompass therapeutic medications designed to manage and treat the symptoms of atopic dermatitis, a chronic inflammatory skin condition marked by itchy and inflamed patches of skin. The necessity for these drugs is driven by the significant prevalence of atopic dermatitis globally, which impacts both pediatric and adult populations, leading to demand for effective treatments that offer relief and improve life quality. The application scope primarily covers topical treatments, systemic drugs, and biologics, with end-users ranging from hospitals, pharmacies, online retailers, and dermatology clinics. Key growth factors include heightened awareness of skin health, increased healthcare expenditure, advancements in biotechnology, and a growing pipeline of innovative drugs such as monoclonal antibodies and JAK inhibitors. Recent opportunities emerge from expanding the use of biologics, which target inflammation pathways with high specificity, and the potential for personalized medicine, which tailors treatments based on genetic profiles. However, market growth is challenged by high drug development costs, regulatory hurdles, and the need for extensive clinical trials, coupled with competitive market dynamics and potential side effects associated with some treatments. To seize emerging opportunities, stakeholders should focus on investing in R&D that pushes for the development of more effective and safer biologics, exploring natural and alternative remedies, and leveraging digital therapeutics for monitoring and managing AD symptoms. Proactive engagement in collaborations and partnerships can facilitate knowledge transfer and innovative breakthroughs. Moreover, innovation could aim at creating more cost-effective formulations to broaden accessibility. The nature of the atopic dermatitis drugs market is highly competitive and research-intensive, characterized by constant evolution driven by scientific advancements and patient-centric demand, necessitating agile strategies to stay ahead in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 8.02 billion
Estimated Year [2024] USD 8.56 billion
Forecast Year [2030] USD 12.76 billion
CAGR (%) 6.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atopic Dermatitis Drugs Market

The Atopic Dermatitis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of atopic dermatitis
    • Growing prevalence of food allergies intensifying atopic dermatitis
    • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Rising awareness regarding the availability of treatments for the disease
    • Growing access to treatment in various developing countries
  • Market Challenges
    • Adverse effects associated with the use of medication

Porter's Five Forces: A Strategic Tool for Navigating the Atopic Dermatitis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atopic Dermatitis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atopic Dermatitis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atopic Dermatitis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atopic Dermatitis Drugs Market

A detailed market share analysis in the Atopic Dermatitis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atopic Dermatitis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atopic Dermatitis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atopic Dermatitis Drugs Market

A strategic analysis of the Atopic Dermatitis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and Phosphodiesterases 4 Inhibitors.
  • Based on Route of Administration, market is studied across Injectable ROA, Oral ROA, and Tropical ROA.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of atopic dermatitis
      • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
      • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
      • 5.1.3.2. Growing access to treatment in various developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the use of medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Atopic Dermatitis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Calcineurin Inhibitors
  • 6.4. Corticosteroids
  • 6.5. Phosphodiesterases 4 Inhibitors

7. Atopic Dermatitis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable ROA
  • 7.3. Oral ROA
  • 7.4. Tropical ROA

8. Americas Atopic Dermatitis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Atopic Dermatitis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch Health Companies Inc.
  • 3. Bayer AG
  • 4. Biofrontera AG
  • 5. Bristol-Myers Squibb Company
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Galderma S.A.
  • 9. GlaxoSmithKline PLC
  • 10. LEO Pharma A/S
  • 11. Meda AB
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Regeneron Pharmaceuticals, Inc
  • 16. Sanofi S.A.
  • 17. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ATOPIC DERMATITIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATOPIC DERMATITIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATOPIC DERMATITIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PHOSPHODIESTERASES 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023